Wellbiotec Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 14,599.82 million compared to KRW 7,355.05 million a year ago. Net loss was KRW 81.34 million compared to KRW 5,757.94 million a year ago. Basic loss per share from continuing operations was KRW 1 compared to KRW 96 a year ago. Diluted loss per share from continuing operations was KRW 1 compared to KRW 96 a year ago. Basic loss per share was KRW 1 compared to KRW 102 a year ago.
For the six months, sales was KRW 41,774.71 million compared to KRW 12,924.94 million a year ago. Net income was KRW 3,602.91 million compared to net loss of KRW 7,835.36 million a year ago. Basic earnings per share from continuing operations was KRW 58 compared to basic loss per share from continuing operations of KRW 144 a year ago. Diluted earnings per share from continuing operations was KRW 58 compared to diluted loss per share from continuing operations of KRW 144 a year ago. Basic earnings per share was KRW 58 compared to basic loss per share of KRW 150 a year ago.